<SEC-DOCUMENT>0000912282-15-000356.txt : 20150916
<SEC-HEADER>0000912282-15-000356.hdr.sgml : 20150916
<ACCEPTANCE-DATETIME>20150916113855
ACCESSION NUMBER:		0000912282-15-000356
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20150916
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20150916
DATE AS OF CHANGE:		20150916

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AntriaBio, Inc.
		CENTRAL INDEX KEY:			0001509261
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				273440894
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-54495
		FILM NUMBER:		151109889

	BUSINESS ADDRESS:	
		STREET 1:		1450 INFINITE DRIVE
		CITY:			LOUISVILLE
		STATE:			CO
		ZIP:			80027
		BUSINESS PHONE:		650-847-1919

	MAIL ADDRESS:	
		STREET 1:		1450 INFINITE DRIVE
		CITY:			LOUISVILLE
		STATE:			CO
		ZIP:			80027

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	FITS MY STYLE INC
		DATE OF NAME CHANGE:	20110104
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>antriabio8k_09162015.htm
<TEXT>
<html>
<head>
    <title>antriabio8k_09162015.htm</title>
    <!--Licensed to: sand-->
    <!--Document Created using EDGARizer 2020 5.5.0.0-->
    <!--Copyright 1995 - 2014 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; DISPLAY: inline">UNITED STATES</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; DISPLAY: inline">SECURITIES AND EXCHANGE COMMISSION</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; DISPLAY: inline">WASHINGTON, D.C. 20549</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; DISPLAY: inline">FORM 8-K</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; DISPLAY: inline">CURRENT REPORT</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">Date of Report (Date of earliest event reported): <font style="FONT-WEIGHT: bold">September 16, 2015</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; DISPLAY: inline"><font style="TEXT-DECORATION: underline; DISPLAY: inline">ANTRIABIO, INC.</font></font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">(Name of registrant in its charter)</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="29%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; TEXT-DECORATION: underline; FONT-FAMILY: times new roman; FONT-WEIGHT: bold; DISPLAY: inline"><font style="DISPLAY: inline">Delaware</font></font></div>
</td>
<td valign="top" width="21%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; TEXT-DECORATION: underline; FONT-FAMILY: times new roman; FONT-WEIGHT: bold; DISPLAY: inline"><font style="DISPLAY: inline">000-54495</font></font></div>
</td>
<td valign="top" width="28%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; TEXT-DECORATION: underline; FONT-FAMILY: times new roman; FONT-WEIGHT: bold; DISPLAY: inline"><font style="DISPLAY: inline">27-3440894</font></font></div>
</td>
</tr><tr>
<td valign="top" width="29%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">(State or jurisdiction</font></div>
</td>
<td valign="top" width="21%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">(Commission File</font></div>
</td>
<td valign="top" width="28%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">(IRS Employer</font></div>
</td>
</tr><tr>
<td valign="top" width="29%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">of incorporation or</font></div>
</td>
<td valign="top" width="21%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">Number)</font></div>
</td>
<td valign="top" width="28%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">Identification No.)&#160;</font></div>
</td>
</tr><tr>
<td valign="top" width="29%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">organization)&#160;</font></div>
</td>
<td align="left" valign="top" width="21%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
<td align="left" valign="top" width="28%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-WEIGHT: bold; DISPLAY: inline">1450 Infinite Drive</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; TEXT-DECORATION: underline; FONT-FAMILY: times new roman; FONT-WEIGHT: bold; DISPLAY: inline">Louisville, CO 80027</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160;(Address of principal executive offices)</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; TEXT-DECORATION: underline; FONT-FAMILY: times new roman; FONT-WEIGHT: bold; DISPLAY: inline">(303) 222-2128</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160;(Registrant's telephone number)</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">_______________________</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160;(Former name or former</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160;address, if changed since last report)</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
&#160;</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="3%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: wingdings; DISPLAY: inline">o</font></div>
</td>
<td align="left" valign="top" width="75%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="3%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: wingdings; DISPLAY: inline">o</font></div>
</td>
<td align="left" valign="top" width="75%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="3%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: wingdings; DISPLAY: inline">o</font></div>
</td>
<td align="left" valign="top" width="75%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="3%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: wingdings; DISPLAY: inline">o</font></div>
</td>
<td align="left" valign="top" width="75%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<br>
<div id="PGBRK" style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160; </font></div>
</div>

<div id="PN" style="WIDTH: 100%; PAGE-BREAK-AFTER: always">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160; </font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; DISPLAY: inline">Item 7.01. Regulation FD Disclosure.</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160;</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">On September 16, 2015, we issued the press release attached hereto as Exhibit 99.1.&#160;&#160;In accordance with General Instruction B.2 of Form 8-K, the information set forth herein and in the press release is deemed to be &#8220;furnished&#8221; and shall not be deemed to be &#8220;filed&#8221; for purposes of the Securities Exchange Act of 1934, as amended.&#160;&#160;The information set forth in Item 7.01 of this Current Report on Form 8-K shall not be deemed an admission as to the materiality of any information in this Current Report on Form 8-K that is required to be disclosed solely to satisfy the requirements of Regulation FD.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; DISPLAY: inline">Item 9.01 Financial Statements and Exhibits</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="7%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-WEIGHT: bold; DISPLAY: inline">EXHIBIT</font></div>
</td>
<td align="left" valign="middle" width="71%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-WEIGHT: bold; DISPLAY: inline">DESCRIPTION</font></div>
</td>
</tr><tr>
<td align="left" valign="middle" width="7%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">99.1</font></div>
</td>
<td align="left" valign="middle" width="71%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">Press Release of AntriaBio, Inc. dated September 16, 2015 **</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">** The following exhibit relating to Item 7.01 is intended to be furnished to, not filed with, the SEC pursuant to Regulation FD.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<br>
<div id="PGBRK" style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160; </font></div>
</div>

<div id="PN" style="WIDTH: 100%; PAGE-BREAK-AFTER: always">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160; </font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160; </font></div>
</div>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; DISPLAY: inline">&#160;</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; DISPLAY: inline">SIGNATURES</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160;</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="48%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160;&#160;</font></div>
</td>
<td align="left" colspan="2" valign="top" width="40%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-WEIGHT: bold; DISPLAY: inline">ANTRIABIO, INC.</font></div>
</td>
</tr><tr>
<td align="left" valign="middle" width="48%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160;&#160;</font></div>
</td>
<td align="left" valign="middle" width="5%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
<td align="left" valign="middle" width="47%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160;&#160;</font></div>
</td>
</tr><tr>
<td align="left" valign="middle" width="48%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160;&#160;</font></div>
</td>
<td align="left" valign="middle" width="5%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
<td align="left" valign="middle" width="47%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160;&#160;</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="48%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">DATE:&#160;&#160;September 16, 2015</font></div>
</td>
<td align="left" valign="top" width="5%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">By:</font></div>
</td>
<td align="left" valign="top" width="47%" style="BORDER-BOTTOM: black 2px solid">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline"><font style="DISPLAY: inline">/s/ Morgan Fields</font><font style="DISPLAY: inline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="48%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
<td align="left" valign="top" width="5%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
<td align="left" valign="top" width="47%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">Morgan Fields</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">Chief Accounting Officer</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify">&#160;</div>

<br>
<div id="PGBRK" style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160; </font></div>
</div>

<div id="PN" style="WIDTH: 100%; PAGE-BREAK-AFTER: always">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160; </font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify">&#160;</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; DISPLAY: inline">EXHIBIT INDEX</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="7%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-WEIGHT: bold; DISPLAY: inline">EXHIBIT</font></div>
</td>
<td align="left" valign="middle" width="71%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-WEIGHT: bold; DISPLAY: inline">DESCRIPTION</font></div>
</td>
</tr><tr>
<td align="left" valign="middle" width="7%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">99.1</font></div>
</td>
<td align="left" valign="middle" width="71%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">Press Release of AntriaBio, Inc. dated September 16, 2015 **</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">** The following exhibit relating to Item 7.01 is intended to be furnished to, not filed with, the SEC pursuant to Regulation FD.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160;</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<br>
<div id="PGBRK" style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160; </font></div>
</div>

<div id="PN" style="WIDTH: 100%; PAGE-BREAK-AFTER: always">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160; </font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160; </font></div>
</div>
</div>

<br>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99_1.htm
<DESCRIPTION>PRESS RELEASE DATED SEPTEMBER 16, 2015
<TEXT>
<html>
<head>
    <title>ex99_1.htm</title>
    <!--Licensed to: sand-->
    <!--Document Created using EDGARizer 2020 5.5.0.0-->
    <!--Copyright 1995 - 2014 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">
<div style="TEXT-ALIGN: right"><font style="FONT-WEIGHT: bold">EXHIBIT 99.1</font></div>

<div>&#160;</div>

<div>&#160;</div>

<div style="TEXT-ALIGN: right"><img src="antriabiologo.jpg" alt=""></div>

<div style="TEXT-ALIGN: right"><br>
<br>
&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; DISPLAY: inline">AntriaBio Announces New Product Candidate, AB301, a Weekly GLP-1 Agonist and Basal </font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; DISPLAY: inline">Insulin Combination, for Type 2 Diabetes</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline"><font style="FONT-WEIGHT: bold; DISPLAY: inline">LOUISVILLE, CO &#8211; 09/16/15 &#8211; </font><font style="TEXT-DECORATION: underline; FONT-WEIGHT: bold; DISPLAY: inline">AntriaBio, Inc.</font><font style="FONT-WEIGHT: bold; DISPLAY: inline">&#160;</font>(&#8220;AntriaBio&#8221; or the &#8220;Company&#8221;) (OTCQB: ANTB), a biopharmaceutical corporation developing novel extended release therapies, announced the addition of a new product candidate to its product development pipeline.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">As a potential treatment for patients with type 2 diabetes, <font style="TEXT-DECORATION: underline; DISPLAY: inline">AB301</font>, is a weekly injectable combination of a pegylated human glucagon-like peptide-1 (GLP-1) agonist and <font style="TEXT-DECORATION: underline; DISPLAY: inline">AB101</font>, AntriaBio&#8217;s basal insulin lead product candidate. In vitro and in vivo studies completed to date indicate that AB301 has the potential to be a well-tolerated, effective therapy for type 2 diabetes.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#8220;Our extended release platform is extremely versatile, providing us with the flexibility to develop a range of differentiated long-acting injectable therapies, said Sankaram Mantripragada, Ph.D., Chief Scientific Officer of AntriaBio. &#8220;I am delighted by the team&#8217;s efforts in successfully formulating a weekly GLP-1 agonist and basal insulin combination, which is a significant milestone in the development of insulin therapies.&#8221;</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#8220;We strongly believe there is a potential advantage of combining a GLP-1 agonist with basal insulin to complement glycemic control while attenuating weight gain and hypoglycemic risk,&#8221; said Brian Roberts, M.D., Vice President of Clinical Development of AntriaBio. &#8220;The potential for combination of these two important therapies in a convenient weekly injection is particularly exciting. If we are successful in its development, we are hopeful AB301 can one day become another approach for initiating insulin therapy in patients with type 2 diabetes.&#8221;</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">AntriaBio is currently engaged in additional ongoing preclinical studies of AB301.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; DISPLAY: inline">About AntriaBio, Inc.</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">AntriaBio is a biopharmaceutical company that develops novel extended release therapies by combining proprietary formulation and manufacturing capabilities with well-known molecules to significantly improve standards of care. AntriaBio's lead product candidate is AB101, an injectable once-weekly basal insulin for type 1 and type 2 diabetes that addresses a $11 billion market where the current standard of care is a once-daily basal insulin injection. For more information visit:&#160;<font style="TEXT-DECORATION: underline; DISPLAY: inline">www.antriabio.com</font>.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; DISPLAY: inline">Forward-Looking Statements</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">This release, like many written and oral communications presented by AntriaBio, Inc., and our authorized officers, may contain certain forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and are including this statement for purposes of said safe harbor provisions. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations of the Company, are generally identified by use of words "anticipate," "believe," "estimate," "expect," "intend," "plan," "project," "seek," "strive," "try," or future or conditional verbs such as "could," "may," "should," "will," "would," or similar expressions. Our ability to predict results or the actual effects of our plans or strategies is inherently uncertain. Accordingly, actual results may differ materially from anticipated results. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Except as required by applicable law or regulation, AntriaBio undertakes no obligation to update these forward-looking statements to reflect events or circumstances that occur after the date on which such statements were made.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; DISPLAY: inline">AntriaBio, Inc. Contact:</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">Noopur Liffick</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">VP of Corporate Development</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">(650) 549-4175</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline"><font style="TEXT-DECORATION: underline; DISPLAY: inline">investor-relations@antriabio.com</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">Source: AntriaBio, Inc.</font></div>

<br>
<div id="PGBRK" style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160; </font></div>
</div>

<div id="PN" style="WIDTH: 100%; PAGE-BREAK-AFTER: always">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160; </font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160; </font></div>
</div>
</div>

<br>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>antriabiologo.jpg
<TEXT>
begin 644 antriabiologo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!F17AI9@  34T *@    @ ! $:  4
M   !    /@$;  4    !    1@$H  ,    !  (   $Q  (    0    3@
M      !@     0   &     !4&%I;G0N3D54('8U+C P /_; $,  @$! @$!
M @(" @(" @(#!0,# P,#!@0$ P4'!@<'!P8'!P@)"PD(" H(!P<*#0H*"PP,
M# P'"0X/#0P."PP,#/_; $,! @(" P,#!@,#!@P(!P@,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$( #0
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MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$
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MP:=X<L+I1L\)Z4D2X"J>%NI]OFSR?>RP0$*F"W3BJ:F^HE5DZC@NAW'[+?\
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M#;G(;(.""*[[X _"FV^!GP1\)^#K0((/#>E6^GY7H[1Q@,W_  )LG\:^,O\
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M-?#<?<$5L;5_M++U>=O>CWMLUYVT:ZV5M=_$S[))UI?6<.KOJN_FCY)\?_M
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/ **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
